Metronomic Tegafur‐Uracil Maintenance Therapy in Oral Squamous Cell Carcinoma Following Adjuvant Chemoradiotherapy
Oral Diseases · 05.11.2026
DOI: 10.1111/odi.70563 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, online erschienen am 05.11.2026. Verfasst von Hsueh-Ju Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chung Shan Medical University Hospital.
Abstract (Originalsprache)
Objective
Oral cavity squamous cell carcinoma (OCSCC) is the predominant subtype of head and neck squamous cell carcinoma in Taiwan. Despite the guideline‐recommended adjuvant chemoradiotherapy (CRT) for advanced pathological risk factors, long‐term survival remains suboptimal. We evaluated the efficacy of tegafur‐uracil as metronomic maintenance therapy following adjuvant CRT.
Methods
This single‐center retrospective cohort study analyzed 197 OCSCC patients who underwent curative resection followed by adjuvant CRT. Patients were stratified by receipt of metronomic tegafur‐uracil maintenance therapy. Survival outcomes were assessed using Cox proportional hazards regression and Kaplan–Meier analyses.
Results
Patients receiving metronomic maintenance therapy (49.2%, 97/197) demonstrated favorable survival trends compared with those who did not. Five‐year disease‐free survival and disease‐specific survival rates were 57.4% vs. 53.0% ( p = 0.101), and 70.1% versus 60.8% ( p = 0.092), respectively. Patients with ≥ 2 risk factors—extreme body mass index, positive margins, extranodal extension, and advanced depth of invasion—demonstrated significantly better outcomes following metronomic maintenance therapy. Therapy initiation at 1–3 months post‐CRT and a treatment duration exceeding 12 months were also associated with a better prognosis.
Conclusion
Metronomic tegafur‐uracil maintenance therapy was associated with favorable outcomes, particularly in patients presenting with ≥ 2 identified risk factors. Prospective multicenter validation is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Department of Dentistry, Chung Shan Medical University Hospital, Taichung, Taiwan.
- School of Dentistry, Chung Shan Medical University, Taichung, Taiwan.
- Department of Radiation Oncology, Chung Shan Medical University Hospital, Taichung, Taiwan.
ORCID-Profile: Hsueh-Ju Lu, Ming-Fang Wu
Förderung
- Chung Shan Medical University Hospital
Zitieren
APA
Lu, H. J., Chiu, Y. W., Tseng, H. C., Peng, C. Y., Hsin, C. H., Chuang, C. Y., Wu, M. F., & Huang, W. S. (2026). Metronomic Tegafur‐Uracil Maintenance Therapy in Oral Squamous Cell Carcinoma Following Adjuvant Chemoradiotherapy. Oral Diseases. https://doi.org/10.1111/odi.70563
Vancouver
Lu HJ, Chiu YW, Tseng HC, Peng CY, Hsin CH, Chuang CY, et al. Metronomic Tegafur‐Uracil Maintenance Therapy in Oral Squamous Cell Carcinoma Following Adjuvant Chemoradiotherapy. Oral Diseases. 2026. doi:10.1111/odi.70563
BibTeX
@article{Lu2026,
author = {Lu, Hsueh-Ju and Chiu, Yu-Wei and Tseng, Hsien-Chun and Peng, Chih-Yu and Hsin, Chung-Han and Chuang, Chun-Yi and Wu, Ming-Fang and Huang, Wei-Shiou},
title = {Metronomic Tegafur‐Uracil Maintenance Therapy in Oral Squamous Cell Carcinoma Following Adjuvant Chemoradiotherapy},
journal = {Oral Diseases},
year = {2026},
doi = {10.1111/odi.70563}
}
EUVIMED